353 results on '"Bregante, S"'
Search Results
2. DLI after haploidentical BMT with post-transplant CY
3. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update
4. Second haploidentical stem cell transplantation for primary graft failure
5. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen
6. Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA)
7. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients
8. DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT):A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS, 1 YEAR POST TRANSPLANT: PH-P337
9. UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB): PH-O126
10. PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS IN 489 HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: AETIOLOGY, RISK FACTORS AND IMPACT ON MORTALITY.: PH-O023
11. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
12. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome
13. allogenic hemopoietic stem cell transplant in patients with acute myeloid leukemia prepared with busulfan and fludarabine or thiotepa busulfan and fludarabine a retrospective study
14. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study
15. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions
16. Sjögrenʼs syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT)
17. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients: O383
18. Anti-CD26 monoclonal antibody for the treatment of steroidrefractory acute graft-versus-host disease (SR-GvHD): a report of two prospective studies: O159
19. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
20. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM)
21. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG)
22. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin
23. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study
24. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin
25. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions: P1046
26. Post-transplant CMV reactivation after CBT: the role of delayed immune reconstitution or donorʼs seronegativity?: P756
27. Acute graft-versus-host disease II-IV in 1465 patients: has outcome improved over the past two decades?: O386
28. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study
29. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up
30. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation
31. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation
32. Successful non-invasive management of late-onset haemorrhagic cystitis in intrabone cord blood transplant recipients
33. Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative donor: incidence, risk factors and outcome
34. Immune reconstitution after cord blood transplantation by direct intrabone injection of cells
35. Treatment of chronic graft-versus-host disease with rituximab
36. Reduction of transplant related mortality with time: major improvement for patients allografted with early disease
37. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
38. Allogeneic BMT for refractory Behçet's disease having relapsed following ABMT
39. High-dose erithropoietin in patients with persistent anaemia after allogeneic bone marrow transplantation
40. Molecular relapse of acute lymphoblastic leukaemia after allogeneic haematopoietic stem cell transplantation can be successfully treated with donor lymphocyte infusions
41. Quality of life in 244 recipients of allogeneic bone marrow transplantation
42. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age
43. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation
44. PF780 STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA: THE ROLE OF THE CONDITIONING REGIMEN
45. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants
46. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications
47. Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants
48. Family mismatched allogeneic stem cell transplantationfor myelofibrosis : Report from the chronic malignancies working party of EBMT
49. Improved Outcome of alternative donor transplantation in patients with myelofibrosis: From unrelated to haploidentical family donors
50. DLI after haploidentical BMT with post-transplant CY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.